Literature DB >> 16094622

Comprehensive analysis of the p53 status in mucosal and cutaneous melanomas.

Christian Gwosdz1, Kathrin Scheckenbach, Oliver Lieven, Julia Reifenberger, Andreas Knopf, Henning Bier, Vera Balz.   

Abstract

The abrogation of the function of the "gatekeeper of the genome", p53, is the most prevalent molecular alteration in solid human tumors. Regarding melanomas the involvement of p53 alterations is discussed controversially to date. In order to evaluate the status of p53 in detail, primary tumors and metastases of 63 sporadic cutaneous (CM) and mucosal (MuM) melanomas were examined by immunohistochemistry and sequence analysis of the entire coding region of the p53 transcript, i.e., exons 2 to 11. In addition, loss of heterozygosity (LOH) and loss of allele-specific transcription (LOT) were determined. Accumulation of the p53 protein occurred in most of the CM and MuM specimens (71% and 58%, respectively). In contrast, protein stabilizing p53 mutations were observed in 14% of the CM and no mutation was found in MuM specimens. Two of the aberrations located outside the core domain. LOH was detected in 22% CM and 58% MuM, and LOT in 25% of the CM specimens. The genotype distribution at the polymorphic p53 codon 72 in melanoma patients differed significantly from control subjects. The calculation of odds ratios (OR) and 95% confidence intervals (CI) indicated an increased risk for developing cutaneous melanomas in individuals carrying the Pro-coding allele. Altogether, aberrant p53 expression appears to be a common event in both CM and MuM. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16094622     DOI: 10.1002/ijc.21366

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Prognostic significance of regulators of cell cycle and apoptosis, p16(INK4a), p53, and bcl-2 in primary mucosal melanomas of the head and neck.

Authors:  Manju L Prasad; Snehal G Patel; Jatin P Shah; Stacy Hoshaw-Woodard; Klaus J Busam
Journal:  Head Neck Pathol       Date:  2011-12-13

2.  Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival.

Authors:  Geoffrey E Johnson; Vladimir N Ivanov; Tom K Hei
Journal:  Apoptosis       Date:  2008-06       Impact factor: 4.677

3.  Spindle cell amelanotic lesion of the tongue: a diagnostic and therapeutic challenge.

Authors:  Vinay Kumar; Mridula Shukla; Umakanth Goud; Devendra Kumar Ravi; Mohan Kumar; Manoj Pandey
Journal:  Indian J Surg       Date:  2012-09-07       Impact factor: 0.656

4.  Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma.

Authors:  Elnaz F Firoz; Melanie Warycha; Jan Zakrzewski; Danuta Pollens; Guimin Wang; Richard Shapiro; Russell Berman; Anna Pavlick; Prashiela Manga; Harry Ostrer; Julide Tok Celebi; Hideko Kamino; Farbod Darvishian; Linda Rolnitzky; Judith D Goldberg; Iman Osman; David Polsky
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

5.  P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation.

Authors:  Kelly A Avery-Kiejda; Nikola A Bowden; Amanda J Croft; Lyndee L Scurr; Carla F Kairupan; Katie A Ashton; Bente A Talseth-Palmer; Helen Rizos; Xu D Zhang; Rodney J Scott; Peter Hersey
Journal:  BMC Cancer       Date:  2011-05-27       Impact factor: 4.430

6.  High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy.

Authors:  Gry Irene Magnussen; Ruth Holm; Elisabeth Emilsen; Anne Katrine Ree Rosnes; Ana Slipicevic; Vivi Ann Flørenes
Journal:  PLoS One       Date:  2012-06-12       Impact factor: 3.240

7.  Increased risk of cutaneous melanoma associated with p53 Arg72Pro polymorphism.

Authors:  Peiliang Geng; Yunmei Liao; Zhihua Ruan; Houjie Liang
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

8.  Cisplatin fails to induce puma mediated apoptosis in mucosal melanomas.

Authors:  Marie Kristin Fritsche; Veronika Metzler; Karen Becker; Christian Plettenberg; Clemens Heiser; Benedikt Hofauer; Andreas Knopf
Journal:  Oncotarget       Date:  2015

Review 9.  Metabolic Alterations and Therapeutic Opportunities in Rare Forms of Melanoma.

Authors:  Anna Han; Zachary T Schug; Andrew E Aplin
Journal:  Trends Cancer       Date:  2021-06-11

10.  Dominant effects of Δ40p53 on p53 function and melanoma cell fate.

Authors:  Rie Takahashi; Svetomir N Markovic; Heidi J Scrable
Journal:  J Invest Dermatol       Date:  2013-09-13       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.